Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hypertension 3Diabetes Mellitus, Type 2 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 4Cetuximab 3Bevacizumab 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Cisplatin 2Carboplatin 2Albumin-Bound Paclitaxel 2relacorilant 1Long Interspersed Nucleotide Elements 1Immunotherapy, Adoptive 1Floxuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × relacorilant × 1 year × Clear all
NCT07259317 2026-04-23

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Corcept Therapeutics

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡